Introduction to Zafirlukast
Zafirlukast, marketed under the NDC code 59651-0291 by Aurobindo Pharma Limited, is a leukotriene receptor antagonist used primarily in the treatment of asthma. Here, we will delve into the market analysis and price projections for this medication.
Market Context
The pharmaceutical market is dynamic, influenced by various factors including regulatory changes, patent expirations, and the introduction of new therapies.
Generic Market Impact
Zafirlukast, being a generic medication, is part of a larger market where generic drugs play a significant role. The expiration of patents for blockbuster drugs often leads to an increase in generic sales. For instance, the patent expiration of drugs like Tarceva and Alimta in the NSCLC market has led to a significant shift towards generic alternatives, a trend that could influence other therapeutic areas as well[3].
Price Trends
Current Pricing
As of the latest data, specific price trends for Zafirlukast (NDC 59651-0291) are not detailed in the sources provided. However, we can infer from broader market trends.
General Drug Price Inflation
According to Vizient's Pharmacy Market Outlook, drug price inflation is projected to grow at 3.8% in 2024. This trend is expected to continue into 2025, although the overall drug price inflation rate for 2025 is projected to be 0.00% for Vizient pharmacy program participants[5].
Example Pricing for Similar Generics
For context, the pricing of other generic drugs can provide some insight. For example, the price of Dimethyl Fumarate (NDC 59651-0084), another generic medication by Aurobindo Pharma, has shown fluctuations over recent months, ranging from $0.93238 to $1.08517 per unit[2].
Market Projections
Generic Drug Market Growth
The generic drug market is expected to continue growing due to the increasing demand for cost-effective treatments. Generic versions of drugs like Zafirlukast are likely to benefit from this trend, especially as more patients and healthcare providers seek affordable alternatives to branded medications.
Competition and Market Share
Aurobindo Pharma Limited, the manufacturer of Zafirlukast under NDC 59651-0291, operates in a competitive market. The company's market share and pricing strategies will be influenced by the presence of other generic manufacturers and the overall market demand for asthma treatments.
Regulatory and Patent Considerations
Patent Status
Zafirlukast is a generic drug, which means its patent has already expired. This allows multiple manufacturers to produce the drug, increasing competition and potentially stabilizing or reducing prices.
Regulatory Compliance
Manufacturers like Aurobindo Pharma must comply with regulatory requirements, including those related to the National Drug Code (NDC) and reporting to the Open Payments system. Compliance with these regulations ensures that the drug remains available in the market without interruptions[4].
Consumer and Healthcare Provider Perspectives
Demand for Asthma Treatments
The demand for asthma treatments, including Zafirlukast, is driven by the prevalence of asthma and the need for effective management options. Healthcare providers often prefer generic alternatives due to their cost-effectiveness, which can influence market demand and pricing.
Patient Access and Affordability
Patient access to affordable medications is a critical factor in the market. Generic drugs like Zafirlukast are generally more affordable than their branded counterparts, making them a preferred choice for many patients.
Key Takeaways
- Market Growth: The generic drug market, including Zafirlukast, is expected to grow due to increasing demand for cost-effective treatments.
- Price Stability: While specific price projections for Zafirlukast are not available, the overall drug price inflation rate is expected to be stable or low in 2025.
- Regulatory Compliance: Manufacturers must comply with regulatory requirements to ensure continued market availability.
- Consumer Demand: The demand for affordable asthma treatments drives the market for generic drugs like Zafirlukast.
Frequently Asked Questions (FAQs)
Q: What is Zafirlukast used for?
A: Zafirlukast is used primarily in the treatment of asthma.
Q: Who manufactures Zafirlukast under NDC 59651-0291?
A: Aurobindo Pharma Limited manufactures Zafirlukast under NDC 59651-0291.
Q: What is the current trend in drug price inflation?
A: According to Vizient's Pharmacy Market Outlook, drug price inflation is projected to grow at 3.8% in 2024, with a stable rate projected for 2025.
Q: How does the generic market impact the pricing of Zafirlukast?
A: The generic market can lead to increased competition, potentially stabilizing or reducing prices for medications like Zafirlukast.
Q: What regulatory requirements must manufacturers comply with?
A: Manufacturers must comply with regulations related to the National Drug Code (NDC) and reporting to the Open Payments system.
Cited Sources:
- FindACode: Aurobindo Pharma Limited - List of Drugs - NDC Labeler/Manufacturer.
- DrugPatentWatch: Latest drug prices and trends for NDC 59651-0084.
- Drug-Dev: NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025.
- CMS: Drug Name and National Drug Code (NDC) Reference Data Instructions.
- Vizient Inc.: Pharmacy Market Outlook Summer 2024.
